Scientific insights: Urea cycle disorders
Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired.
Year: 2025
-
-
Scientific insights: Kidney disease
Explore why kidney disease is emerging as a top therapeutic focus. See how VibeOne identifies high-potential kidney indications and guides strategic prioritization.
-
Whitepaper: The AI buying guide for BD&L executives
AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L.
-
Scientific insights: Fabry disease
Fabry disease may seem niche, but it’s becoming a bellwether for how global innovation and modality shifts are reshaping rare disease pipelines.
-
Why BD teams cannot afford to lose their memory & how AI can help
Even with databases, access to prior knowledge in biotech BD teams often breaks down. The antidote is simple : build durable organizational memory. AI can help.
-
Increasing hope in rare disease — how Incite partnered with Vibe Bio to accelerate the search & evaluation of sarcoma drugs
Learn how Incite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis.
-
How Orphan Therapeutics Accelerator is optimizing rare disease search & eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
-
From overwhelm to clarity: prioritizing assets with AI-powered confidence
Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.
-
Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking.
-
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
